Even with apparent indicators of efficacy, clinicians still have questions about using Biogen, Inc. and Eisai Co., Ltd.’s Leqembi (lecanimab-irmb) in Alzheimer’s disease patients. Many likely require more study and some could be limiting uptake.
Leqembi has no guidance on when treatment should end, Erik Musiek, an associate neurology professor at Washington University School of Medicine, said during a Health and Human Services Department Advisory...